SCHEMBL1305816

SCHEMBL1305816

CC(NC(=O)C(=CCCCCC(=O)NO)COc1cccc2ccccc12)C1C=CCCC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.37
▸ CASP3 P42574 4/20 0.36
▸ CASP1 P29466 3/20 0.36
▸ CASP7 P55210 3/20 0.36
▸ CASP8 Q14790 3/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ CASP6 P55212 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ OGG1 O15527 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ PREP P48147 1/20 0.35
▸ ADAMTS4 O75173 1/20 0.35
▸ ADAMTS5 Q9UNA0 1/20 0.35
▸ HDAC3 O15379 1/20 0.34
▸ HDAC4 P56524 1/20 0.34
▸ HDAC1 Q13547 1/20 0.34
▸ HDAC7 Q8WUI4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1305810 1.00 ALDH1A1 (0.37) ALDH1A1CASP3CASP1CASP7CASP8
SCHEMBL1305884 0.92 ALDH1A1 (0.41) ALDH1A1CASP3CASP1CASP7CASP8
SCHEMBL1306814 0.92 CNR2 (0.38) ALDH1A1CASP3CASP1CASP7CASP8
SCHEMBL1306578 0.87 P2RX3 (0.46) ALDH1A1CASP3CASP1CASP7CASP8
SCHEMBL1306583 0.87 P2RX3 (0.46) ALDH1A1CASP3CASP1CASP7CASP8
SCHEMBL1305813 0.83 ADAMTS4 (0.41) ALDH1A1MEN1KMT2AKDM4EHPGD
SCHEMBL1305161 0.81 P2RX3 (0.46) ALDH1A1CASP3CASP1CASP7CASP8
SCHEMBL27762656 0.80 CASP3 (0.39) ALDH1A1CASP3CASP1CASP7CASP8
SCHEMBL1306543 0.80 HDAC3 (0.42) ALDH1A1CASP3KMT2AKDM4EHPGD
SCHEMBL29488463 0.80 HDAC3 (0.42) ALDH1A1CASP3KMT2AKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220287993-A1 PHARMACEUTICAL COMPOSITION COMPRISING HDAC INHIBITOR AND ANTI-PD1 ANTIBODY OR ANTI PD-L1 ANTIBODY CRYSTALGENOMICS, INC. (KR) 2022-09-15 — — US claimed
WO-2022177054-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 INFECTION 크리스탈지노믹스(주) 2022-08-25 — — WO claimed
EP-4026544-A1 PHARMACEUTICAL COMPOSITION COMPRISING HDAC INHIBITOR AND ANTI-PD1 ANTIBODY OR ANTI PD-L1 ANTIBODY Crystalgenomics, Inc. (KR) 2022-07-13 — — EP claimed
US-20210346321-A1 PHARMACEUTICAL COMPOSITION CONTAINING ALKYL CARBAMOYL NAPHTHALENYLOXY OCTENOYL HYDROXYAMIDE PHOSPHATE, TARTRATE OR COMBINATION THEREOF, AND PREPARATION METHOD THEREFOR CRYSTALGENOMICS, INC. (KR) 2021-11-11 — — US claimed
EP-3875081-A1 PHARMACEUTICAL COMPOSITION CONTAINING ALKYL CARBAMOYL NAPHTHALENYLOXY OCTENOYL HYDROXYAMIDE PHOSPHATE, TARTRATE OR COMBINATION THEREOF, AND PREPARATION METHOD THEREFOR Crystalgenomics, Inc. (KR) 2021-09-08 — — EP claimed
WO-2021045392-A1 PHARMACEUTICAL COMPOSITION COMPRISING HDAC INHIBITOR AND ANTI-PD1 ANTIBODY OR ANTI PD-L1 ANTIBODY 크리스탈지노믹스(주) 2021-03-11 — — WO claimed
US-20200283371-A1 PHARMACEUTICALLY ACCEPTABLE SALT OF ALKYLCARBAMOYL NAPHTHALENYLOXY OCTENOYLHYDROXYAMIDE OR OF DERIVATIVE THEREOF AND METHOD FOR PREPARING SAME CRYSTALGENOMICS, INC. (KR) 2020-09-10 — — US claimed
EP-3640239-A1 PHARMACEUTICALLY ACCEPTABLE SALT OF ALKYLCARBAMOYL NAPHTHALENYLOXY OCTENOYLHYDROXYAMIDE OR OF DERIVATIVE THEREOF AND METHOD FOR PREPARING SAME Crystalgenomics, Inc. (KR) 2020-04-22 — — EP claimed
EP-2913322-A2 Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same Korea Research Institute Of Chemical Technology (KR) 2015-09-02 — — EP claimed
US-8053435-B2 Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2011-11-08 — — US claimed
US-20100069630-A1 NAPHTHALENYLOXYPROPENYL DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-03-18 — — US claimed
US-11655207-B2 Pharmaceutically acceptable salt of alkylcarbamoyl naphthalenyloxy octenoylhydroxy amide or of derivative thereof and method for preparing same CRYSTALGENOMICS, INC. (KR) 2023-05-23 — — US disclosed
EP-4155292-A1 METHOD FOR PRODUCING PHARMACEUTICALLY ACCEPTABLE SALT OF ALKYLCARBAMOYL NAPHTHALENYLOXY OCTENOYLHYDROXYAMIDE Crystalgenomics, Inc. (KR) 2023-03-29 — — EP disclosed
US-20220287993-A1 PHARMACEUTICAL COMPOSITION COMPRISING HDAC INHIBITOR AND ANTI-PD1 ANTIBODY OR ANTI PD-L1 ANTIBODY CRYSTALGENOMICS, INC. (KR) 2022-09-15 — — US disclosed
WO-2022177054-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 INFECTION 크리스탈지노믹스(주) 2022-08-25 — — WO disclosed
US-20200283371-A1 PHARMACEUTICALLY ACCEPTABLE SALT OF ALKYLCARBAMOYL NAPHTHALENYLOXY OCTENOYLHYDROXYAMIDE OR OF DERIVATIVE THEREOF AND METHOD FOR PREPARING SAME CRYSTALGENOMICS, INC. (KR) 2020-09-10 — — US disclosed
EP-3640239-A1 PHARMACEUTICALLY ACCEPTABLE SALT OF ALKYLCARBAMOYL NAPHTHALENYLOXY OCTENOYLHYDROXYAMIDE OR OF DERIVATIVE THEREOF AND METHOD FOR PREPARING SAME Crystalgenomics, Inc. (KR) 2020-04-22 — — EP disclosed
EP-2913322-A2 Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same Korea Research Institute Of Chemical Technology (KR) 2015-09-02 — — EP disclosed
US-8053435-B2 Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2011-11-08 — — US disclosed
US-20100069630-A1 NAPHTHALENYLOXYPROPENYL DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-03-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220287993-A1 PHARMACEUTICAL COMPOSITION COMPRISING HDAC INHIBITOR AND ANTI-PD1 ANTIBODY OR ANTI PD-L1 ANTIBODY PDCD1, HDAC1, HDAC5 ALDH1A1 348/4885CASP3 118/4885CASP1 120/4885
US-20210346321-A1 PHARMACEUTICAL COMPOSITION CONTAINING ALKYL CARBAMOYL NAPHTHALENYLOXY OCTENOYL HYDROXYAMIDE PHOSPHATE, TARTRATE OR COMBINATION THEREOF, AND PREPARATION METHOD THEREFOR AGPAT5, NOTUM, HADH ALDH1A1 3493/4885CASP3 3456/4885CASP1 2924/4885
US-11655207-B2 Pharmaceutically acceptable salt of alkylcarbamoyl naphthalenyloxy octenoylhydroxy amide or of derivative thereof and method for preparing same DOHH, CYP51A1, ASAH2 ALDH1A1 851/4885CASP3 2663/4885CASP1 3673/4885
US-20100069630-A1 NAPHTHALENYLOXYPROPENYL DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME HDAC1, HDAC3, HDAC11 ALDH1A1 673/4885CASP3 542/4885CASP1 2439/4885
US-20200283371-A1 PHARMACEUTICALLY ACCEPTABLE SALT OF ALKYLCARBAMOYL NAPHTHALENYLOXY OCTENOYLHYDROXYAMIDE OR OF DERIVATIVE THEREOF AND METHOD FOR PREPARING SAME DOHH, CYP51A1, CYP46A1 ALDH1A1 690/4885CASP3 2757/4885CASP1 3678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback